Overcoming clinical inertia in type 2 diabetes

Webinar

This webinar ran Wednesday 16th November 2022

  • 12:00-13:00 GMT
  • 13:00-14:00 CET
  • 21:00-22:00 JST

Melanie Davies is joined by Paola Fioretto and Francesc Xavier Cos in this discussion- and case-based webinar aiming to look at the causes and consequences of clinical inertia in T2D management and strategies to avoid it. Aimed at endocrinologists, diabetologists and primary care practitioners worldwide who provide front-line care of patients with diabetes.

Clinical experts

Melanie Davies
Melanie Davies (UK)
Program director and Chair
Professor of Diabetes Medicine, University of Leicester, Diabetes Research Centre
Bio
Francesc Xavier Cos
Francesc Xavier Cos (Spain)
Innovation and research officer; University Professor; Primary Care Specialist; Institut Català de la Salut
Bio
Paola Fioretto
Paola Fioretto (Italy)
Professor of Medicine, Department of Medicine, University of Padova
Bio

Event registration

By registering, you will receive:

  • Communications about the live event
  • Notifications when the on-demand recording of this event and supporting materials are available
Melanie Davies

Melanie Davies

Professor of Diabetes Medicine, University of Leicester, Diabetes Research Centre

Melanie Davies is a clinician with over 25 years’ experience working as a diabetologist and physician, and since 2006 is a Professor of Diabetes Medicine at the University of Leicester, in the UK. She is a National Institute of Health Research (NIHR) Senior Investigator, one of only a handful in diabetes in the UK, Director of the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, Director of a Clinical Trial Unit, Lead for Division 2 of the Clinical Research Network East Midlands and Principal Investigator on a number of large global studies in the field of diabetes, obesity and cardiovascular disease.

Professor Davies is the global PI on the SCALE Obesity trial, a large multinational study investigating management of obesity with GLP-1 analogue.

She has had more than 180 peer review publications and has been awarded over £30,000,000 of external reviewed grant funding.

Disclosures

Honoraria or consultation fees - Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, AstraZeneca, Janssen, Lexicon, Pfizer, ShouTi Pharma Inc
Participation in a company sponsored speaker bureau - Napp Pharmaceuticals, Novartis and Takeda Pharmaceuticals International Inc

Paola Fioretto

Paola Fioretto

Professor of Medicine, Department of Medicine, University of Padova

Paola Fioretto is Professor in Medicine at the University of Padova, Italy. She started her research on renal physiology in diabetes and, during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes. Among her contributions to the understanding of diabetic kidney disease are the descriptions of the heterogeneity in the structural lesions underlying renal dysfunction in type 2 diabetes, and of reversal of established diabetic glomerulopathy lesions in patients with type 1 diabetes after pancreas transplantation.

Professor Fioretto’s research interest includes the effects of glucose-lowering therapies on the development and progression of diabetic kidney disease.

She has received several awards, including the Albert Renold award from the EASD (European Association for the Study of Diabetes), a Career Development Award from JDFI, the Morgagni Young Investigator Award, the Novartis Young Investigator, the Italian Society of Diabetology Award, and the Golgi Prize from the EASD. She has been Vice President of the EASD (2014-2017), and President of the European Diabetic Nephropathy Study Group of the EASD (2005-2007). She has published over 190 papers and 30 book chapters.

Disclosures

Honoraria or consultation fees - AstraZeneca, Boehringer Ingelheim, Lilly, Mundipharma, Bayer, Novo.

Francesc Xavier Cos

Francesc Xavier Cos

Innovation and research officer; University Professor; Primary Care Specialist; Institut Català de la Salut

Francesc Xavier Cos is a GP in Sant Martí Primary Health Centres and innovation and research officer at Institut Català de la Salut, Barcelona ( Spain). His main areas of interest are Innovation, research and Education in health His background in Primary Care has special relevance in the field of Diabetes.

Dr Cos is a member and European representative in Diabetes and Endocrine disorders of the Primary Care University Research Institute Jordi Gol, where he is an active member in 2 working groups: Diabetes Prevention and Epidemiological Database analysis. He started his activities on Diabetes at GEDAPS “Primary Care Diabetes Study Group” in 1997.

He has worked on many institutional projects for the Catalonian Health Department, and is regularly invited to participate in national and international ( LATAM, Middle East,...) meetings to lecture on Diabetes in Primary Care, to develop and conduct educational activities and to develop.

Dr Cos works on various research projects in Diabetes prevention and has been involved in many randomized clinical trials. He is also involved as an Associate Professor at the medicine department of the Universitat Autonoma de Barcelona since 2009 and is an associate editor of the Primary Care Diabetes journal. In 2009 he was elected as vice chairman of the Primary Care Diabetes Europe and in February 2016 as Chairman elect. In February 2017 he was appointed as Chairman of PCDE for 4 years.

Disclosures

Grants/research support - AstraZeneca, Novartis, SANOFI, Boehringer Ingelheim
Honoraria or consultation fees - AstraZeneca, ABBOTT, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, Sanofi Pasteur, Esteve
Participation in a company sponsored speaker bureau - AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Sanofi Diabetes, Sanofi Pasteur